Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Norimitsu Okui

Matched on ORCID iD 0000-0002-7993-5794; OpenAlex author ID A5082172237. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers · 2026: 2 papers

Papers 12

  1. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  2. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.21873/cdp.10600↗
  3. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. Co-author DOI 10.1007/s00595-024-02882-2↗
  4. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  5. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Co-author DOI 10.1177/00031348241272420↗
  6. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  7. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  8. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.01.003↗
  9. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  10. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  11. Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.10.009↗
  12. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life. Co-author DOI 10.1186/1477-7819-11-3↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 10 shared papers, 2023–2026 · strength 2.30
  2. Yoshihiro Shirai · 10 shared papers, 2023–2026 · strength 2.30
  3. Masashi Tsunematsu · 9 shared papers, 2023–2026 · strength 2.09
  4. Kenei Furukawa · 9 shared papers, 2023–2026 · strength 2.09
  5. Koichiro Haruki · 9 shared papers, 2023–2026 · strength 2.03
  6. Shinji Onda · 8 shared papers, 2023–2026 · strength 1.79
  7. Michinori Matsumoto · 7 shared papers, 2023–2026 · strength 1.58
  8. Takeshi Gocho · 5 shared papers, 2024–2026 · strength 1.20
  9. Taro Sakamoto · 4 shared papers, 2024–2026 · strength 0.95
  10. Ryoga Hamura · 3 shared papers, 2025–2026 · strength 0.76
  11. Shunta Ishizaki · 3 shared papers, 2023–2025 · strength 0.63
  12. Tadashi Uwagawa · 3 shared papers, 2023–2025 · strength 0.61
  13. Tadashi Uwagawa · 3 shared papers, 2019–2025 · strength 0.59
  14. Yoshiaki Tanji · 2 shared papers, 2026 · strength 0.53
  15. Yuta Yamada · 2 shared papers, 2025–2026 · strength 0.51
  16. Mitsuru Yanagaki · 2 shared papers, 2024–2025 · strength 0.45
  17. Yosuke Igarashi · 2 shared papers, 2024–2025 · strength 0.43
  18. Takashi Aida · 1 shared paper, 2026 · strength 0.26
  19. Kyohei Abe · 1 shared paper, 2025 · strength 0.22
  20. Tomohiko Taniai · 1 shared paper, 2024 · strength 0.21
  21. Katsuhiko K. Yanaga · 2 shared papers, 2013–2019 · strength 0.13
  22. Sadamu Homma · 1 shared paper, 2019 · strength 0.10
  23. Yoichi Toyama · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.